RA NPV Forecast Calculator

Risk-Adjusted NPV forecast model with Basic and Advanced inputs – one indication, one geography
This Risk-Adjusted Net Present Value (RA NPV) forecast calculator is a useful metric to compare several programs in terms of their risk and value. For example, an early-stage (i.e., riskier) product with higher revenue potential may be as attractive as a late-stage (i.e., less risky) product with lower revenue potential.


Notably, the RA NPV calculator is an expanded version of our Non-risk adjusted (NRA) NPV calculator. Specifically, RA NPV incorporates probabilities of success (PoS) for each development phase.


Overall, RA NPV calculations include Revenue, Costs, Cash Flow, and Risk parameters. For description of Revenue inputs, please check our Revenue Calculator. For description of Costs and Cash Flow inputs, please check our NRA NPV calculator. Here, Risk is expressed using PoS for each phase of development as described below in more detail.


Lastly, to find out which input makes the biggest difference in NPV, go to the NPV Sensitivity Analysis tool.
Risk-Adjusted NPV:
BioHeights

BioHeights

BioHeights
BioHeights.com
Download: Charts Image · Inputs CSV · Data CSV

submit
Probability of Success In Details
Confused? Stuck? Please send any questions, comments, and requests to bioheights@pm.me. We will respond quickly.

Please Subscribe below to receive email notifications about new tools and blog posts. Also, check out our blog articles on the Insights page.

Disclaimer: This risk-adjusted NPV forecast model/ calculator is the property of BioHeights LLC. We designed this model only for educational purposes. Importantly, this is not a financial advice. BioHeights LLC and its members are not responsible for anybody’s actions, losses, or damages resulting from using this model.

Sign Up to Receive the Latest Insights
Enter your email address to receive notifications about new articles, tools, and updates.
Sign Up Here

Solve a Problem: Oncology Product rNPV

Drug for Acute Lymphoblastic Leukemia (ALL). Can treat ~20% of patients, with a single dose, one-time infusion. Preclinical stage of development. U.S. market. Exclusivity loss in 2033. No competition. Price per dose $475k. Cost per dose $50k. R&D $500M. Launch Expenses $100M. Royalties 5%.

1. For the Preclinical product, how does risk-adjusted NPV (rNPV) compare to non-risk adjusted NPV? Use the following assumptions: Preclinical PoS = 80%. Preclinical, Ph1, Ph2, Registration - 1 year each, Ph3 – 2 years.
  X   NPV negative, rNPV positive
  X   No difference
  X   NPV > rNPV, both positive
  V   NPV positive, rNPV negative

2. How would rNPV change when the product progresses from Preclinical to Phase 2? Use the following assumptions: remaining R&D for the Phase 2 product is $400M. Adjust loss of exclusivity for Ph2 product to 2031 for relevant comparison.
  V   -$59M : -$38M
  X   $59M : -$24M
  X   -$59M : -$24M
  X   $4.3M : -$38M